IP Library Granted Patent US 7,951,613
Granted Patent B2
US 7,951,613 · App. 12/553,765 · Granted May 31, 2011

Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion

Assignee: CBIO Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,613
App. No.
12/553,765
Granted
May 31, 2011
Kind
B2
Abstract

Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example being IL-10. These immunoregulatory activities of Cpn10 may be useful in the treatment of diseases, disorders and conditions resulting from excessive pro-inflammatory cytokine and chemokine secretion. This invention also relates to producing, designing and/or screening Cpn10 agonists and antagonists according to their ability to regulate Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion.

Claims (5)

1. A method of screening for a Chaperonin 10 (Cpn10) antagonist comprising the steps of:

forming a molecular complex comprising a Toll-like receptor, a Toll-like receptor agonist and Cpn10 in the presence and absence of a candidate Cpn10 antagonist; and

detecting whether formation of the molecular complex is prevented or disrupted by the presence of the candidate Cpn10 antagonist;

wherein a candidate Cpn10 antagonist detected to prevent or disrupt formation of the molecular complex is identified as a Cpn10 antagonist.

2. The method of claim 1 , wherein the Toll-like receptor is selected from the group consisting of TLR2 and TLR4.

Assignments (1)
PATENT AND TRADEMARK SECURITY AGREEMENT Recorded Apr 17, 2015
From: INVION LIMITED
To: MCP MANAGER PTY LTD, AS TRUSTEE FOR AND FOR THE BENEFIT OF THE MCP UNIT TRUST 2014
Reel/Frame 035450/0502 →
Priority Claims (2)
AU 2004900190 · Jan 16, 2004 · national
AU 2004903914 · Jul 16, 2004 · national
Continuity (2)
Continuation 10586143
Related Publication 20090325882A1 · Dec 31, 2009